| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias |
| LGIN: Low-grade intraepithelial neoplasias |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ |
| IAC: Invasive lung adenocarcinoma |
| MIA: Minimally invasive adenocarcinoma |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia |
| NEOLP: Non-erosive oral lichen planus |
| OSCC: Oral squamous cell carcinoma |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma |
| SCCIS:squamous cell carcinoma in situ |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis |
| PTC: Papillary thyroid cancer |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00346441 | Liver | HCC | cellular response to UV | 56/7958 | 90/18723 | 1.25e-04 | 1.03e-03 | 56 |
| GO:000975521 | Liver | HCC | hormone-mediated signaling pathway | 106/7958 | 190/18723 | 1.45e-04 | 1.17e-03 | 106 |
| GO:00714782 | Liver | HCC | cellular response to radiation | 104/7958 | 186/18723 | 1.48e-04 | 1.19e-03 | 104 |
| GO:003052121 | Liver | HCC | androgen receptor signaling pathway | 31/7958 | 44/18723 | 1.63e-04 | 1.30e-03 | 31 |
| GO:005159121 | Liver | HCC | response to cAMP | 57/7958 | 93/18723 | 1.96e-04 | 1.52e-03 | 57 |
| GO:003033021 | Liver | HCC | DNA damage response, signal transduction by p53 class mediator | 46/7958 | 72/18723 | 2.02e-04 | 1.56e-03 | 46 |
| GO:0009411 | Liver | HCC | response to UV | 85/7958 | 149/18723 | 2.34e-04 | 1.77e-03 | 85 |
| GO:00103321 | Liver | HCC | response to gamma radiation | 37/7958 | 56/18723 | 3.13e-04 | 2.22e-03 | 37 |
| GO:001407421 | Liver | HCC | response to purine-containing compound | 84/7958 | 148/18723 | 3.19e-04 | 2.26e-03 | 84 |
| GO:00714802 | Liver | HCC | cellular response to gamma radiation | 23/7958 | 31/18723 | 3.47e-04 | 2.42e-03 | 23 |
| GO:001072011 | Liver | HCC | positive regulation of cell development | 155/7958 | 298/18723 | 5.39e-04 | 3.48e-03 | 155 |
| GO:0033182 | Liver | HCC | regulation of histone ubiquitination | 11/7958 | 12/18723 | 5.97e-04 | 3.75e-03 | 11 |
| GO:00062824 | Liver | HCC | regulation of DNA repair | 74/7958 | 130/18723 | 6.27e-04 | 3.89e-03 | 74 |
| GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
| GO:00180221 | Liver | HCC | peptidyl-lysine methylation | 74/7958 | 131/18723 | 8.46e-04 | 5.06e-03 | 74 |
| GO:000863011 | Liver | HCC | intrinsic apoptotic signaling pathway in response to DNA damage | 58/7958 | 99/18723 | 8.97e-04 | 5.29e-03 | 58 |
| GO:00063021 | Liver | HCC | double-strand break repair | 131/7958 | 251/18723 | 1.17e-03 | 6.54e-03 | 131 |
| GO:004668321 | Liver | HCC | response to organophosphorus | 73/7958 | 131/18723 | 1.52e-03 | 8.05e-03 | 73 |
| GO:001097511 | Liver | HCC | regulation of neuron projection development | 220/7958 | 445/18723 | 1.68e-03 | 8.78e-03 | 220 |
| GO:0010976 | Liver | HCC | positive regulation of neuron projection development | 88/7958 | 163/18723 | 1.98e-03 | 1.00e-02 | 88 |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KDM1A | SNV | Missense_Mutation | | c.1189G>C | p.Glu397Gln | p.E397Q | O60341 | protein_coding | tolerated(0.07) | possibly_damaging(0.552) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| KDM1A | SNV | Missense_Mutation | | c.812G>A | p.Arg271Gln | p.R271Q | O60341 | protein_coding | deleterious(0.04) | probably_damaging(0.941) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KDM1A | SNV | Missense_Mutation | | c.2426N>G | p.Ser809Trp | p.S809W | O60341 | protein_coding | deleterious(0) | possibly_damaging(0.803) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| KDM1A | SNV | Missense_Mutation | | c.1189N>A | p.Glu397Lys | p.E397K | O60341 | protein_coding | deleterious(0.01) | benign(0.413) | TCGA-W8-A86G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| KDM1A | insertion | Nonsense_Mutation | novel | c.677_678insATAGAGATGGAGAAGAATATTATTCCAAGCATACATTAATGT | p.Thr226_Gln227insTer | p.T226_Q227ins* | O60341 | protein_coding | | | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| KDM1A | insertion | Nonsense_Mutation | novel | c.1919_1920insGATGACAGTTGAGGATTCTGAAGTTGAC | p.Tyr640Ter | p.Y640* | O60341 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
| KDM1A | insertion | Frame_Shift_Ins | novel | c.1816_1817insGAGCGTGGTGGCTCATGCCTGTAATACCAGCACTT | p.Leu606ArgfsTer13 | p.L606Rfs*13 | O60341 | protein_coding | | | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| KDM1A | SNV | Missense_Mutation | | c.817C>A | p.His273Asn | p.H273N | O60341 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KDM1A | SNV | Missense_Mutation | novel | c.358T>C | p.Tyr120His | p.Y120H | O60341 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.991) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KDM1A | SNV | Missense_Mutation | novel | c.1844G>T | p.Arg615Leu | p.R615L | O60341 | protein_coding | deleterious(0.02) | possibly_damaging(0.69) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | inhibitor | 178103603 | | |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | inhibitor | 310264760 | | |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | TRANYLCYPROMINE HYDROCHLORIDE | TRANYLCYPROMINE HYDROCHLORIDE | |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | 2-[N-(PHTHALIMIDO)]ETHYL CARBAMIMIDOTHIOATE HCL | CHEMBL2182009 | 22876979 |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | inhibitor | 249565921 | | |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | activator | 252166601 | | |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | inhibitor | 178103602 | | |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | inhibitor | 178101964 | TRANYLCYPROMINE | |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | PARNATE | PARNATE | 21382717 |
| 23028 | KDM1A | DRUGGABLE GENOME, ENZYME, CELL SURFACE, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | NAMOLINE | NAMOLINE | 24007511 |